Literature DB >> 6202773

Characteristics of amplifier T cells involved in the antibody response to the capsular polysaccharide of type III Streptococcus pneumoniae.

C E Taylor, P W Stashak, J Chiang, W M Leiserson, G Caldes, B Prescott, P J Baker.   

Abstract

Amplifier T cell activity can be transferred by spleen cells harvested 72 hr after priming with type III pneumococcal polysaccharide (SSS-III) and can be abolished by treating the transferred cells with monoclonal anti-Lyt-1, or anti-Thy-1 antibodies in the presence of complement; thus, amplifier cells represent a distinct subpopulation of T cells. Amplifier T cells were found to be sensitive to irradiation but not to treatment with cyclophosphamide. When amplifier cells were transferred to athymic nude (nu/nu) mice, the enhancement obtained was much greater than that produced in thymus-bearing (nu/+) mice; this is presumably due to the lack of suppressor T cell activity in nu/nu mice that enables amplifier T cell activity to be expressed more fully. Amplifier T cells also were found to be present in peripheral blood; these amplifier T cells were Lyt-2- in phenotype. Although the induction and activation of amplifier T cells appear to be antigen-specific, the product made by amplifier T cells may not be antigen specific in its mode of action. Because amplifier T cells can be induced and activated by exposure to immune B cells, specificity is presumably due in whole or in part to the ability of amplifier T cells to recognize the idiotypic determinants of B cell-associated antibody specific for SSS-III.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202773

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes.

Authors:  P J Baker
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

2.  Genes on different chromosomes influence the antibody response to bacterial antigens.

Authors:  P J Baker; D W Bailey; M B Fauntleroy; P W Stashak; G Caldes; B Prescott
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

Review 3.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

4.  Interleukin 2 receptor expression by human blood lymphocytes after vaccination with pneumococcal polysaccharides.

Authors:  N Tvede; C Heilmann; L D Christensen
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

5.  Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A.

Authors:  P J Baker; J R Hiernaux; M B Fauntleroy; B Prescott; J L Cantrell; J A Rudbach
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

6.  T-cell modulation of the antibody response to bacterial polysaccharide antigens.

Authors:  C E Taylor; R Bright
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

7.  Induction of a macrophage-suppressive lymphokine by soluble cryptococcal antigens and its association with models of immunologic tolerance.

Authors:  R Blackstock; J M McCormack; N K Hall
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

8.  Immunoregulatory role of the spleen in antibody responses to pneumococcal polysaccharide antigens.

Authors:  D A Cohn; G Schiffman
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

9.  Prior exposure to subimmunogenic amounts of some bacterial lipopolysaccharides induces specific immunological unresponsiveness.

Authors:  K L Elkins; P W Stashak; P J Baker
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

10.  Amplifier T cell activity is decreased in MRL/1 mice: failure of concanavalin A and anti-lymphocyte serum to enhance antibody responses to thymus-independent antigens.

Authors:  D A Wilson; H Braley-Mullen
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.